{'fraction_non_alphanumeric': 0.039755351681957186, 'fraction_numerical': 0.022935779816513763, 'mean_word_length': 5.925925925925926, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Selection of patients with symptomatic diabetic neuropathy for clinical trials.

Two hundred and fourteen patients with prima-facie evidence of symptomatic diabetic neuropathy were considered for inclusion in a clinical trial. Only 50 patients (24%) fulfilled all the clinical and electrophysiological criteria for entry. One hundred and nine patients (51%) were excluded on clinical grounds alone. Reasons for exclusion included the presence of alternative causes of neuropathy (15%), peripheral vascular disease (10%), proximal or asymmetrical neuropathies (11%), renal impairment (5%), nerve entrapment (4%), cerebrovascular disease (2%) and amputations (2%) with miscellaneous conditions accounting for the remaining 2%. Of the 105 patients who satisfied the clinical entry requirements another 55 patients (26%) were excluded by electrophysiological criteria. Peroneal motor nerve conduction velocity was unrecordable or unacceptably reduced (less than 30 m/s) in 42% of these patients, sensory nerve potentials were unrecordable in 8% and median nerve compression was evident in another 3%. The selection of cohorts for clinical trials in diabetic neuropathy involves careful consideration of clinical and electrophysiological features of the patients and exclusion of alternative causes of neuropathy.